This article first appeared on GuruFocus. ADMA Biologics Inc (NASDAQ:ADMA) is set to release its Q4 2025 earnings on February 25, 2026. The consensus estimate for Q4 2025 revenue is $139.40 million, ...
ADMA Biologics is a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients ...
CEO Adam Grossman recently sold company shares under a pre-arranged Rule 10b5-1 trading plan. The transaction also included the exercise of stock options, indicating a mix of share sale and option ...
Strategic Plasma Network Repositioning Expected to Enhance Margins and Strengthen Long-Term Supply Visibility Positive, Statistically Significant Real-World ASCENIV(TM) Outcomes to be Presented at CIS ...
ADMA Biologics ADMA reported lower-than-expected results for the first quarter. Adjusted earnings per share of 14 cents missed the Zacks Consensus Estimate of 16 cents. Revenues of $114.8 million (up ...
Zacks Investment Research on MSN
Adma Biologics (ADMA) ascends while market falls: Some facts to note
In the latest trading session, Adma Biologics (ADMA) closed at $16.32, marking a +2.06% move from the previous day. This move outpaced the S&P 500's daily loss of 0.28%. Meanwhile, the Dow lost 0.54%, ...
The MarketWatch News Department was not involved in the creation of this content. 3Q 2025 Total Revenue of $134.2 Million, a 12% YoY Increase 3Q 2025 GAAP Net Income of $36.4 Million, a 1% YoY ...
ADMA Biologics shows robust revenue growth, driven by its innovative IVIG product, ASCENIV, which targets primary humoral immunodeficiency and includes RSV antibodies. Q4 earnings reveal a 59% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results